Herantis Pharma Oyj Management
Management criteria checks 2/4
Herantis Pharma Oyj's CEO is Antti Vuolanto, appointed in Jul 2022, has a tenure of 2.5 years. directly owns 0.012% of the company’s shares, worth €3.82K. The average tenure of the management team and the board of directors is 4.3 years and 3.8 years respectively.
Key information
Antti Vuolanto
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.5yrs |
| CEO ownership | 0.01% |
| Management average tenure | 4.3yrs |
| Board average tenure | 3.8yrs |
CEO
Antti Vuolanto (49 yo)
2.5yrs
Tenure
Dr. Antti Vuolanto, D.Sc. (Tech) serves as Chief Executive Officer of Herantis Pharma Oyj since July 2022. He served as Chief Operating Officer at Herantis Pharma Oyj since February 2018. Dr. Vuolanto serv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 2.5yrs | no data | 0.012% € 3.8k | |
| Chief Financial Officer | 4.3yrs | no data | 0.056% € 18.3k | |
| Chief Scientific Officer | 14.9yrs | no data | 0.40% € 129.8k | |
| Head of CMC | no data | no data | no data | |
| Chief Medical Ofcer | no data | no data | no data | |
| Clinical Consultant | no data | no data | no data |
4.3yrs
Average Tenure
55yo
Average Age
Experienced Management: HRTIS's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | 11yrs | no data | 0.0079% € 2.6k | |
| Chairman of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Independent Chairman of the Board | 13yrs | no data | 0.076% € 24.9k | |
| Director | 4.8yrs | no data | no data | |
| Director | 11yrs | no data | 0.14% € 44.6k | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Director | 3.8yrs | no data | 0.0099% € 3.3k | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data |
3.8yrs
Average Tenure
65yo
Average Age
Experienced Board: HRTIS's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 03:27 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Herantis Pharma Oyj is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Viktor Sundberg | ABG Sundal Collier Sponsored |
| Susie Jana | Edison Investment Research |
| Petri Gostowski | Inderes Oy |